Impact of Single-pill Combination Therapy on Adherence, Blood Pressure Control, and Clinical Outcomes: a Rapid Evidence Assessment of Recent Literature
Overview
Affiliations
Objective: The 2018 European Society of Cardiology/European Society of Hypertension Guidelines for the management of arterial hypertension raised the need for evidence to support the use of single-pill combination (SPC) therapy in preference to free-dosed therapy for hypertension. This systematic rapid evidence assessment sought to determine if initiating SPC therapy improves adherence, blood pressure (BP) control and/or cardiovascular outcomes vs. initiation of free-dose combination therapy.
Methods: Rapid evidence assessment conducted in MEDLINE, EMBASE, and Cochrane Library (1 January 2013-11 January 2019) to identify studies investigating SPC therapy for adults with hypertension. Information on adherence/persistence, BP lowering/goal attainment, and cardiovascular outcomes/events were extracted via two-phase screening process. Studies not focusing on adherence, persistence, or compliance with SPC therapy were excluded. Methodological quality was assessed using appropriate scales.
Results: Of 863 citations, 752 failed to meet inclusion or were duplicates. Twenty-nine studies remained following full-text screening. Just four studies (14%) were randomized controlled studies; 25 (86%) were observational. A range of SPC therapies were studied, with calcium channel blocker/angiotensin receptor blocker combinations most common (11/29 studies). Adherence and persistence were generally higher with SPC vs. free-dose combination therapy; 15 studies (54%) directly compared adherence and four (14%) compared persistence. Patients achieving BP targets ranged from 25 to 89%. Despite all studies investigating patients with hypertension only 16 (55%) reported change in BP. Few studies reported on cardiovascular outcomes. Methodological reporting was often suboptimal.
Conclusion: Adherence and/or persistence were generally higher in patients taking antihypertensives as SPC vs. free-dose combination; however, methodological reporting was suboptimal to facilitate comparison. Specifically designed, well reported studies are required to determine if the increased adherence/persistence seen in patients on SPC regimen leads to improved BP control and/or cardiovascular outcomes.
Novel pharmacological approaches to lowering blood pressure and managing hypertension.
Sayer M, Webb D, Dhaun N Nat Rev Cardiol. 2025; .
PMID: 39920248 DOI: 10.1038/s41569-025-01131-4.
Systemic hypertension in adults with congenital heart diseases.
Sabatino J, Avesani M, Sirico D, Reffo E, Castaldi B, Bassareo P Int J Cardiol Congenit Heart Dis. 2024; 13:100456.
PMID: 39712235 PMC: 11658137. DOI: 10.1016/j.ijcchd.2023.100456.
Simonyi G, Burnier M, Narkiewicz K, Rokszin G, Abonyi-Toth Z, Kovacs G J Hypertens. 2024; 43(3):405-412.
PMID: 39641301 PMC: 11789606. DOI: 10.1097/HJH.0000000000003916.
Naydenov S, Manov E, Runev N J Cardiovasc Dev Dis. 2024; 11(9).
PMID: 39330337 PMC: 11432305. DOI: 10.3390/jcdd11090279.
Li S, Tan I, Atkins E, Schutte A, Gnanenthiran S Curr Heart Fail Rep. 2024; 21(4):322-336.
PMID: 38861130 PMC: 11333539. DOI: 10.1007/s11897-024-00672-y.